Clinical Trial: Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07804186) titled 'Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma' on Aug. 21.

Brief Summary: This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Uveal Melanoma

Intervention: DRUG: Darovasertib

Oral, selectively targets key proteins

DRUG: Crizotinib (Xalkori)

Oral small molecule

Recruitment Status: RECRUITING

Sponsor: IDEAYA Biosciences

Disclaimer: Curated by HT Syndication....